Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 15/20 | 0.95 |
| ▸ | MMP2 | P08253 | 9/20 | 0.95 |
| ▸ | MMP1 | P03956 | 12/20 | 0.55 |
| ▸ | MMP3 | P08254 | 9/20 | 0.55 |
| ▸ | MMP7 | P09237 | 6/20 | 0.55 |
| ▸ | MMP13 | P45452 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7308416 | 1.00 | MMP9 (0.95) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7305533 | 0.97 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7305528 | 0.97 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL8524352 | 0.87 | MMP9 (0.72) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7305247 | 0.85 | MMP9 (0.70) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL8525263 | 0.85 | MMP9 (0.70) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL27476403 | 0.85 | MMP9 (0.70) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL27432261 | 0.85 | MMP9 (0.70) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL31630322 | 0.84 | MMP9 (0.76) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7302697 | 0.83 | MMP9 (0.74) | MMP9MMP2MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0780386-B1 | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-5932595-A | ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT | SYNTEX (U.S.A.) INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |